Please assess the completion status of the following clinical trial:

Trial Title: LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or above~* Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the Body Surface Area (BSA)~* A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk and limbs~* A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and limbs.~Exclusion Criteria:~* Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis~* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:~  * etanercept - within 4 weeks prior to randomisation~ * adalimumab, infliximab - within 8 weeks prior to randomisation~ * ustekinumab - within 16 weeks prior to randomisation~ * other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer)~* Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants within 4 weeks prior to randomisation)~* Subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.~* Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to randomisation~* Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation~* Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation~* Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation~* Females who are pregnant, wishing to become pregnant during the trial or are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 90100 (Type: EXPERIMENTAL): LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
- Aerosol foam vehicle (Type: PLACEBO_COMPARATOR): Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
- Calcipotriol BDP gel (Type: ACTIVE_COMPARATOR): Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
- Gel vehicle (Type: PLACEBO_COMPARATOR): Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).